| US 7,524,980 B2 | ||
| Vitamin D3 lactam derivative | ||
| Kazuo Nagasawa, Tokyo (Japan); Yuichi Hashimoto, Tokyo (Japan); and Yuko Kato, Hino (Japan) | ||
| Assigned to Teijin Pharma Limited, Tokyo (Japan) | ||
| Filed on Nov. 04, 2004, as Appl. No. 10/980,253. | ||
| Claims priority of provisional application 60/516727, filed on Nov. 04, 2003. | ||
| Prior Publication US 2005/0182032 A1, Aug. 18, 2005 | ||
| Int. Cl. C07C 401/00 (2006.01); C07C 403/00 (2006.01); C07D 207/00 (2006.01); A01N 45/00 (2006.01); A61K 31/59 (2006.01) | ||
| U.S. Cl. 552—653 [548/552; 514/167] | 8 Claims |
1. A vitamin D3 derivative expressed by the following formula (1)
 [wherein, R1 is selected from an octyl group, a 3-phenylpropyl group, a 4-phenylbutyl group, a 2-naphthylmethyl group, and a 4-methoxybenzyl
group], or a pharmaceutically permissible solvate thereof, wherein the solvent used to convert the vitamin D3 derivative of formula (1) into a solvate is water, methanol, ethanol, 1-propanol, 2propanol, butanol, 2-methyl-2propanol,
acetonitrile, acetone, methyl ethyl ketone, chloroform, ethyl acetate, diethyl ether, t-butyl methyl ether, benzene, toluene,
DMF or DMSO.
|